astria therapeutics glp-1 receptor agonist weight management diabetes treatments GLP-1-based therapies for diabetes, obesity and beyond GLP-1 therapies: a new frontier

Louis Aronne, a principal investigator on the clinical trial involving Zepbound and Wegovy, told ABC News that the success of drugs using tirzepatide is likely because the ingredient targets two hormones instead of one

Effects of Glucose-Lowering Drugs on Cardiovascular Outcomes in Patients with Type 2 Diabetes: An Update

This canonical pathway promotes insulin granule exocytosis while simultaneously suppressing inappropriate glucagon secretion from -cells [51,52]

Interpreting the Evidence GLP-1 receptor agonists intersect with several antagonistic hallmarks of aging, particularly those linking mitochondrial function, nutrient sensing, and cellular senescence

Convenient, have wonderful doctors who listen to your concerns

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials